News

Feds want more trial results made public

The Department of Health and Human Services and the National Institutes of Health are proposing new rules that would greatly expand the number of clinical trials required to publicize their results, a move that could change how CROs handle data.

Medidata and TransCelerate beat the drum for risk-based monitoring

Medidata and partner TransCelerate BioPharma, a nonprofit run by the world's largest drugmakers, are amplifying their call for clinical trial runners to embrace new technology, unveiling study results that support the adoption of risk-based monitoring.

PRA and INC trade up amid a warm reception for CRO debuts

PRA Health Sciences and INC Research have both seen their shares tick upward since pulling off IPOs earlier this month, a sign that, despite biotech's boom and bust, the window for CRO debuts remains open.

Parexel recruits NextDocs to its stable of eClinical collaborators

NextDocs, a venture-backed document-management company, has signed a deal with Parexel to integrate its services with the CRO's growing eClinical platform.

AMRI gets its desert branch back online after a profit-sapping outage

After a weather-related shutdown at a New Mexico facility helped tank its quarterly earnings, AMRI has rectified the issue, bringing its plant back online as it works to get back on the path to growth.

CRO Ricerca stays alive after buyer swoops in

Ohio-headquartered CRO Ricerca Biosciences can put off its liquidation plans, as the company has found an acquirer to keep its doors open just ahead of a self-imposed deadline.

Devicemaker Consort buys into the CDMO space with Aesica deal

The U.K.'s Consort Medical has closed its $374 million buyout of contract drug developer Aesica, part of an effort to diversify its offerings and expand the market for its proprietary drug delivery devices.

Recipharm trades $140M for a Portuguese CDMO

Pharma outsourcer Recipharm has acquired a Portuguese contract drug developer for €112.3 million ($140 million) in cash and stock, bolstering its global scale and further consolidating the world of R&D service providers.

Parexel eyes logistics with latest EU expansion

Parexel International has cut the ribbon on a new clinical trial supply hub in Europe, centralizing the CRO's continental logistics services as part of a companywide effort to more efficiently conduct studies around the globe.

Catalent makes another buy and ticks up its revenue

Catalent has acquired another R&D tech firm, snapping up Micron Technologies and its particle sizing capabilities as the recently IPO'd company works to expand its share of the drug development market.

WuXi ups its revenue ambitions after M&A and expansion

Chinese CRO WuXi PharmaTech is forecasting a better-than-expected 2014 after a strong third quarter and some timely deals, moving into the new year with hopes for continued global growth.

Charles River deepens its ties to Huntington's R&D with new deal

Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.

India's GVK snags an early-stage CRO amid global growth

Indian CRO GVK Biosciences is expanding its capacity in early-phase R&D, buying a local preclinical testing outfit as it works to expand its reach.

FDA taps Icon to help patients better weigh in on trials

Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.

PPD teams up with Medidata on risk-based monitoring

PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.

AMRI tanks on disappointing sales and a dimmer outlook

Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.

WuXi reaches into Israel with a new office and a local partnership

Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.

PRA raises the stakes, eyeing $400M in a blockbuster IPO

CRO conglomerate PRA is angling to be the next contract drug developer to make a splash on Wall Street, setting terms for a $400 million IPO.

CRO Paragon raises $13M to expand its footprint

Baltimore CRO Paragon Bioservices has raised a $13 million A round, money it'll spend to stretch out its offerings in biologics R&D and manufacturing.

LabCorp is buying Covance for $5.6B to cut in on the CRO boom

Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.